The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with ¹³¹I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to approximately 25,000 members of ThyCa: Thyroid Cancer Survivors’ Association, Inc., and was available online from March to August 2018. Responses were included from adult patients regarding their most recent ¹³¹I therapy received between 2011 and 2018 (“after 2011”). Responses to this survey were compared with those of a similar previous survey for ¹³¹I therapies received between 1997 and 2009 (“before 2009”). Results: Of the 2,136 responses, 1,111 met the inclusion criteria. A similar percentage (∼98%) of patients were given oral or written radiation safety instructions (RSIs) after 2011 and before 2009, with a shift away from nuclear medicine physicians providing instructions after 2011 (43%) in comparison with before 2009 (54%; P < 0.001). More patients were able to discuss and individualize the RSIs after 2011 (67%) than before 2009 (29%; P < 0.001). However, 2% of patients do not recall ever receiving RSIs after 2011. After 2011, more patients were treated as outpatients (87%) than before 2009 (66%; P < 0.001). For outpatients, more patients were discharged within 30 min after receiving ¹³¹I therapy after 2011 (78%) than before 2009 (72%; P = 0.002). The same percentage (0.6%) of patients traveled more than 2 h with at least 2 occupants in the vehicle within approximately 1 m of the patient after 2011 and before 2009. Immediately after therapy, a similar percentage of patients stayed in a nonprivate residence after 2011 (4%) and before 2009 (5%; P = 0.28). Of the 27 outpatients released within 30 min to nonprivate residences, 2 patients received 5.55–11.1 GBq (150–299 mCi) of ¹³¹I. Conclusion: This survey suggests that since publication of the Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 on patient release after radioiodine therapy, there have been improvements in some radiation safety practices on release of outpatients, as well as improvements in patient compliance on travel and lodging.

这项全国性调查的目的是评估自核监管委员会2011年1月《管理问题摘要》发布以来，用¹³¹ I治疗的分化型甲状腺癌患者在医院释放方面的做法是否发生了变化。方法：将调查问卷通过电子邮件发送给ThyCa：甲状腺癌幸存者协会，公司，约25,000名会员，该调查于2018年3月至8月在线提供。包括成年患者对2011年至2018年间接受的最新¹³¹ I治疗的回复（“ 2011年之后”）。将此调查的回复与之前类似调查的^{131进行了比较}我在1997年至2009年（“ 2009年之前”）之间接受了治疗。结果：在2136份答复中，有1111份符合纳入标准。2011年之后和2009年之前，有类似百分比（〜98％）的患者接受了口服或书面放射安全指导（RSI），与2009年之前相比，2011年后（43％）的核医学医师有所改变（54 ％；P <0.001）。与2009年之前（29％；P <0.001）相比，2011年之后（67％）能够讨论和个性化RSI的患者更多。但是，有2％的患者在2011年之后没有回想起曾接受过RSI。2011年之后，被门诊治疗的患者（87％）比2009年之前的患者（66％; P<0.001）。对于门诊患者，2011年之后接受¹³¹ I治疗后30分钟内出院的患者（78％）比2009年之前（72％；P = 0.002）。2011年之后和2009年之前，相同百分比（0.6％）的患者旅行了2小时以上且车辆中至少有2名乘员，距离患者约1 m。在治疗后，相似百分比的患者在旅行后住在非私人住所2011年（4％）和2009年之前（5％; P = 0.28）。在30分钟内释放到非私人住所的27位门诊患者中，有2位患者接受了¹³¹ I的5.55-11.1 GBq（150-299 mCi）。结论： 这项调查表明，自从核监管委员会2011年1月发布关于放射性碘治疗后患者释放的监管问题摘要以来，门诊患者释放放射治疗方面的一些安全措施已有所改善，并且患者出行和就寝的依从性得到了改善。